A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2015
At a glance
- Drugs Sapanisertib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Millennium
- 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 15 Nov 2013 Planned end date changed from 1 Sep 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.